TrialAmerican journal of hematology2015

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

Carlo Gambacorti-Passerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.